| 000 | 01755 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517135207.0 | ||
| 264 | 0 | _c20170424 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1523-1747 | ||
| 024 | 7 |
_a10.1016/j.jid.2017.01.013 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTrousil, Sebastian | |
| 245 | 0 | 0 |
_aPhenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. _h[electronic resource] |
| 260 |
_bThe Journal of investigative dermatology _c05 2017 |
||
| 300 |
_a1135-1143 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNeurofibromin 1 _xgenetics |
| 650 | 0 | 4 |
_aOxygen Consumption _xdrug effects |
| 650 | 0 | 4 |
_aPhenformin _xadministration & dosage |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 700 | 1 | _aChen, Shuang | |
| 700 | 1 | _aMu, Chan | |
| 700 | 1 | _aShaw, Fiona M | |
| 700 | 1 | _aYao, Zhan | |
| 700 | 1 | _aRan, Yuping | |
| 700 | 1 | _aShakuntala, Tiwari | |
| 700 | 1 | _aMerghoub, Taha | |
| 700 | 1 | _aManstein, Dieter | |
| 700 | 1 | _aRosen, Neal | |
| 700 | 1 | _aCantley, Lewis C | |
| 700 | 1 | _aZippin, Jonathan H | |
| 700 | 1 | _aZheng, Bin | |
| 773 | 0 |
_tThe Journal of investigative dermatology _gvol. 137 _gno. 5 _gp. 1135-1143 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jid.2017.01.013 _zAvailable from publisher's website |
| 999 |
_c26836075 _d26836075 |
||